Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer

Abstract

Background

It is important to seek the appropriate chemotherapy drugs to effectively eliminate colorectal cancers. To avoid unnecessary medication and uncomfortable side effects, it is important to estimate the chemosensitivity of cancers to 5-fluorouracil (5-FU) before chemotherapy.

Methods

We examined thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) gene expressions in 23 colorectal cancers, using quantitative reverse transcription-polymerase chain reaction (RT-PCR). We then evaluated the relationship between TS and DPD gene expression levels and the sensitivity of colorectal cancers to 5-FU, as determined by histoculture drug response assay (HDRA).

Results

A significant increase in the TS expression score was observed in 5-FU-sensitive colorectal cancers (0.57 ± 0.19) compared to 5-FU-resistant ones (1.16 ± 0.98; P = 0.029), whereas no significant differences in DPD expression scores were observed in 5-FU-sensitive colorectal cancers (0.86 ± 1.19) compared to 5-FU-resistant ones (0.56 ± 1.05; P = 0.603).

Conclusions

TS mRNA may be useful as a predictor of the 5-FU chemosensitivity of colorectal cancers.